Agonist of the PGE2 receptor EP4
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

CAY10598

Item No. 13281

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
5-[(3S)-3-hydroxy-4-phenyl-1-buten-1-yl]1-[6-(2H-tetrazol-5R-yl)hexyl]-2-pyrrolidinone
CAS Number
346673-06-1
Molecular Formula
C21H29N5O2
Formula Weight
383.5
Purity
≥98%
Formulation
A 5 mg/ml solution in ethanol
Solubility(Learn about Variance in Solubility)
DMF: 12.5 mg/mlDMSO: 12.5 mg/mlEthanol: 15 mg/mlPBS (pH 7.2): 1.4 mg/ml
SMILES
O=C1N(CCCCCCC2=NN=NN2)[C@](/C=C/[C@@H](O)CC3=CC=CC=C3)([H])CC1
InChi Code
InChI=1S/C21H29N5O2/c27-19(16-17-8-4-3-5-9-17)13-11-18-12-14-21(28)26(18)15-7-2-1-6-10-20-22-24-25-23-20/h3-5,8-9,11,13,18-19,27H,1-2,6-7,10,12,14-16H2,(H,22,23,24,25)/b13-11+/t18-,19+/m0/s1
InChi Key
JWYPJSNXPZTEHL-VJKINUSGSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $106

    Add

    1 mg

    $148

    Add

    5 mg

    $579

    Add

    10 mg

    $1,050

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    CAY10598 is a very potent agonist of EP4, binding with a Ki value of 1.2 nM.1 Moreover, it does not bind EP1, EP2, EP3, or other prostanoid receptors, including DP, FP, IP, and TP.1 First generation EP4 receptor-selective agonists have been shown to reduce inflammation, improve bone healing, provide cardio- and neuroprotection, and reduce renal dysfunction, suggesting some clinical applications for EP4 agonists.2,3,4,5,6

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Billot, X., Chateauneuf, A., Chauret, N., et al. Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. Bioorg. Med. Chem. Lett. 13(6), 1129-1132 (2003).

    2. Yamane, H., Sugimoto, Y., Tanaka, S., et al. Prostaglandin E2 receptors, EP2 and EP4, differentially modulate TNF-α and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. Biochem. Biophys. Res. Commun. 278, 224-228 (2000).

    3. Marui, A., Hirose, K., Maruyama, T., et al. Prostaglandin E2 EP4 receptor-selective agonist facilitates sternal healing after harvesting bilateral internal thoracic arteries in diabetic rats. J. Thorac. Cardiovasc. Surg. 131(3), 587-593 (2006).

    4. Xiao, C.Y., Yuhki, K.i., Hara, A., et al. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109, 2462-2468 (2004).

    5. Ahmad, A.S., Ahmad, M., de Brum-Fernandes, A.J., et al. Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res. 1066, 71-77 (2005).

    6. Li, J.H., Chou, C.L., Li, B., et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J. Clin. Invest. 119(10), 3115-3126 (2009).

    Product Citations

    Ching, M.M., Reader, J., and Fulton, A.M. Eicosanoids in cancer: Prostaglandin E2 receptor 4 in cancer therapeutics and immunotherapy. Front. Pharmacol. 11, 819 (2020).